Retension Pharmaceuticals: CEO and a new director buy at $12 — score 66/100

A sitting CEO and a director with no prior stake both bought at $12.00 on the same day. Total: $369,600.00 across two separate filings.

In this brief: 3 sections 2 min read

- • Keller Eric L. (Chief Executive Officer) — 20,800 shares @ $12.00, $249,600.00, +5.2%
- • BERGER FRANKLIN M (Director) — 10,000 shares @ $12.00, $120,000.00, new position
- Position growth (20 of 20) and seniority (15 of 15) carry this cluster: a CEO bought, and the director's stake went from nothing to 10,000 shares. Dollar size is the brake at 15.7 of a possible 35 — $369,600.00 is modest on the log-scaled scale. No same-day selling and no excluded rows, so there are no penalties.
- • The 2026-10-13 date is when the Form 4s were filed; the trades themselves were executed within 2026-10-07 – 2026-10-13.
- • Every figure above is taken from the filings as reported, not estimated.
- • This is a record of what insiders did and how the score was computed. It is not investment advice.

Useful?